AxoGen, Inc. Earnings Recaps
Q3 2025
Oct 29, 2025
AxoGen delivered strong Q3 2025 results with revenue reaching $60.1 million, a 23.5% year-over-year growth, driven by robust demand across all nerve repair target markets.
Key takeaways
- Q3 sales increased to $60.1 million, with double-digit growth in extremities, oral maxillofacial, and breast markets.
- High potential accounts contributed approximately 64% of revenue growth year-to-date, despite a transition phase affecting growth metrics.
- Strong surgeon adoption of the AxoGen nerve care algorithm, particularly in mandible reconstruction and breast resensation procedures.
- Successful completion of the hiring plan for commercial expansion, particularly in the breast resensation sales force.
- Anticipation of BLA approval for Avance Nerve Graft in December 2025, expected to enhance market positioning.